JP2024538573A - 免疫刺激剤としてのアゴニスト性cd40抗体 - Google Patents

免疫刺激剤としてのアゴニスト性cd40抗体 Download PDF

Info

Publication number
JP2024538573A
JP2024538573A JP2024518745A JP2024518745A JP2024538573A JP 2024538573 A JP2024538573 A JP 2024538573A JP 2024518745 A JP2024518745 A JP 2024518745A JP 2024518745 A JP2024518745 A JP 2024518745A JP 2024538573 A JP2024538573 A JP 2024538573A
Authority
JP
Japan
Prior art keywords
antibody
cancer
fragment
region
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538573A5 (cg-RX-API-DMAC7.html
Inventor
フィッシャー、シュテファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAB Discovery GmbH
Original Assignee
MAB Discovery GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAB Discovery GmbH filed Critical MAB Discovery GmbH
Publication of JP2024538573A publication Critical patent/JP2024538573A/ja
Publication of JP2024538573A5 publication Critical patent/JP2024538573A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024518745A 2021-10-01 2022-09-30 免疫刺激剤としてのアゴニスト性cd40抗体 Pending JP2024538573A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21200496.4 2021-10-01
EP21200496 2021-10-01
PCT/EP2022/077270 WO2023052581A1 (en) 2021-10-01 2022-09-30 Agonistic cd40 antibodies as immune stimulatory agents

Publications (2)

Publication Number Publication Date
JP2024538573A true JP2024538573A (ja) 2024-10-23
JP2024538573A5 JP2024538573A5 (cg-RX-API-DMAC7.html) 2025-10-07

Family

ID=78078007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518745A Pending JP2024538573A (ja) 2021-10-01 2022-09-30 免疫刺激剤としてのアゴニスト性cd40抗体

Country Status (7)

Country Link
US (1) US20240392026A1 (cg-RX-API-DMAC7.html)
EP (1) EP4408537A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024538573A (cg-RX-API-DMAC7.html)
CN (1) CN118139886A (cg-RX-API-DMAC7.html)
AU (1) AU2022358474A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232917A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023052581A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534292A (ja) * 2017-09-19 2020-11-26 エムエービー ディスカバリー ゲーエムベーハー アゴニスト性cd40抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534292A (ja) * 2017-09-19 2020-11-26 エムエービー ディスカバリー ゲーエムベーハー アゴニスト性cd40抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF IMMUNOLOGY, vol. Vol.195, Issue.3, JPN6026030349, 2015, pages 1015 - 1024, ISSN: 0005913158 *

Also Published As

Publication number Publication date
CN118139886A (zh) 2024-06-04
US20240392026A1 (en) 2024-11-28
CA3232917A1 (en) 2023-04-06
AU2022358474A1 (en) 2024-03-28
EP4408537A1 (en) 2024-08-07
WO2023052581A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
JP7701964B2 (ja) Cd137及びox40に結合する抗体分子
CN112088167B (zh) 特异性针对人类连接蛋白4的抗体
US20230348619A1 (en) Combination Of T-Cell Redirecting Multifunctional Antibodies With Immune Checkpoint Modulators And Uses Thereof
JP6629187B2 (ja) 免疫活性化抗原結合分子
JP7754895B2 (ja) アゴニスト性cd40抗体
CA2930218C (en) Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
TWI760352B (zh) 抗icos抗體
US20240209061A1 (en) Fusion proteins and uses thereof
KR20180004277A (ko) Pdl-1 항체, 그 약학적 조성물 및 그 용도
KR20180102628A (ko) 면역조절제의 조합물에 의한 암의 치료
US20210380700A1 (en) De-adcc/cdc functions of antibodies and their applications
TW202313682A (zh) 抗icos抗體之用途
KR20240046905A (ko) 항-TIGIT 항체 및 TGF-βR을 포함하는 융합 단백질, 이의 약학 조성물, 및 용도
JP2022554374A (ja) 抗tigit抗体及びその使用
JP2024520638A (ja) 抗icos抗体によるpd-l1陰性または低発現がんの処置
US20230365714A1 (en) Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
JP2021523688A (ja) 抗cd27抗体およびその使用
US20240392026A1 (en) Agonistic cd40 antibodies as immune stimulatory agents
JP2025514847A (ja) Fas軸拮抗薬及びTreg細胞枯渇剤拮抗薬を含む癌の治療のための併用療法
EP4469476A1 (en) Combination therapy for the treatment of cancer
RU2817602C2 (ru) Молекулы антител, которые связывают cd137 и ox40
RU2825839C2 (ru) Антитела, специфичные к нектину-4 человека
JP2026048723A (ja) Pd-l1に結合する多重特異性結合化合物
HK40116729A (en) Fusion protein comprising tgf-beta rii extracellular region fragment, pharmaceutical composition and use thereof
JP2024518843A (ja) 抗icos抗体の使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240624

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260721